Bevacizumab in Advanced Hepatocellular Carcinoma: NCT07813572 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 3
Clinical phase
Not yet recruiting
Recruitment status
600
Planned enrollment
2031-09-01
Primary-completion proxy
Executive view
NCT07813572 evaluates Bevacizumab in Advanced Hepatocellular Carcinoma. The disclosed sponsor is Suzhou Zelgen Biopharmaceuticals Co., Ltd., the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Progression-free survival (PFS), assessed over up to 3 years.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07813572 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Advanced Hepatocellular Carcinoma landscape. Drug & Asset MCP drug_fetch was queried for Bevacizumab, while Company & Deal Intelligence MCP organization_fetch was queried for Suzhou Zelgen Biopharmaceuticals Co., Ltd..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07813572 | Bevacizumab | Phase 3 / Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | China | Progression-free survival (PFS) up to 3 years | 2031-09-01 |
| NCT07806292 | Anlotinib Dihydrochloride | Phase 2 / Recruiting | Sun Yat-Sen Memorial Hospital | China | objective response rate (ORR) 12 months | 2026-12-31 |
| NCT07801287 | Lenvatinib mesylate | Phase 2 / Recruiting | Tianjin Medical University Cancer Institute and Hospital | China | Incidence of TEAEs From date of randomization until the occurrence of adverse events ass… | 2028-08-15 |
| NCT07790419 | Tislelizumab | Phase 4 / Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | China | Disease-free survival (DFS) From the date of randomization until the date of first documented rec… | 2028-12-31 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07813572 is a Phase 3, not yet recruiting study with 600 planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “Progression-free survival (PFS)” over “up to 3 years.” The retrieved endpoint description is: PFS evaluated by the Blinded Independent Review Committee (IRC) based on RECIST V1.1.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 600 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
The protocol identifies Sintilimab, Bevacizumab as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
4 recent result records were selected as contextual evidence for Advanced Hepatocellular Carcinoma. These records do not establish direct evidence for NCT07813572 unless the registration number matches.
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475)…
Phase 3; n=480; Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)(Median): Hazard Ratio (HR) = 0.66(95% CI, 0.51 - 0.84), P-Value = 0.0002; Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)(Median): Hazard Rat… Source: https://clinicaltrials.gov/ct2/show/results/NCT04246177
Early Detection, Accurate Staging, and Biologic Characterization of HCC With Hybrid 68Ga-PSMA-Dual -Contrast PET/MRI and PET/CT Using Cyclotron-Produced 68Ga
Phase 2; n=52; High PSMA uptake, grade 3 or 4 = 25 HCC Lesions Source: https://clinicaltrials.gov/ct2/show/results/NCT04762888
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, op…
Phase 2/3; n=226; Adverse Event: acute renal failure = 3% of patients in the atezolizumab plus bevacizumab group experienced acute renal failure ; Adverse Event: acute renal failure = 3% of patients in the atezolizumab plus bevacizumab group experienced acute renal failure Source: https://pubmed.ncbi.nlm.nih.gov/42330996/
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Bevacizumab is indexed as Monoclonal antibody with VEGF-A biology and a global stage of Approved. The asset profile lists Genentech, Inc. as an originator or developer.
Suzhou Zelgen Biopharmaceuticals Co., Ltd. is indexed in China with the website http://www.zelgen.com. Researches, develops, manufactures and distributes threespecific antibody medicines The record lists 22 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Bevacizumab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07813572
Protocol source: https://clinicaltrials.gov/study/NCT07813572
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.
Bevacizumab in Advanced Hepatocellular Carcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Progression-free survival (PFS) and 2031-09-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
